Toggle light / dark theme

In 2005, University of California, Berkeley, researchers made the surprising discovery that making conjoined twins out of young and old mice—such that they share blood and organs—can rejuvenate tissues and reverse the signs of aging in the old mice. The finding sparked a flurry of research into whether a youngster’s blood might contain special proteins or molecules that could serve as a “fountain of youth” for mice and humans alike.

But a new study by the same team shows that similar age-reversing effects can be achieved by simply diluting the of old mice—no needed.

In the study, the team found that replacing half of the blood plasma of old mice with a mixture of saline and albumin—where the albumin simply replaces that was lost when the original blood plasma was removed—has the same or stronger rejuvenation effects on the brain, liver and muscle than pairing with young mice or young blood exchange. Performing the same procedure on had no detrimental effects on their health.

Why does this happen?

To put things as simply as possible, the root cause of all aging is a loss of energy on the cellular level, and there are basically two major theories for why this occurs. One says cellular energy decline is the result of accumulated cellular and mitochondrial damage. In other words, it’s the result of wear and tear on a cellular level. The other theory speculates that it is the result of genetic programming, with some genes getting overexpressed while others get underexpressed as we age.

These two theories of cellular energy decline aren’t in competition with one another. They just look at the problem from two different vantage points. The reality is these “causes” are interrelated. Gene overexpression and underexpression can cause cellular damage. Cellular damage can impair gene expressions.

I remember I looked over a study from the Lancet. I questioned it. I have also read other studies, and I have questioned them. At least I know my questioning was within reason now. People can not spike studies and expect to get away with it, as the truth always comes out in the end.


Two major study retractions in one month have left researchers wondering if the peer review process is broken.

Two people with beta thalassaemia and one with sickle cell disease no longer require blood transfusions, which are normally used to treat severe forms of these inherited diseases, after their bone marrow stem cells were gene-edited with CRISPR.

Result of the ongoing trial, which is the first to use CRISPR to treat inherited genetic disorders, were announced today at a virtual meeting of the European Hematology Association.

This is really old news:

Two tried-and-true vaccines — a century-old inoculation against tuberculosis and a decades-old polio vaccine once given as a sugar cube — are being evaluated to see if they can offer limited protection against the coronavirus.


The old vaccines are oddities among the cutting-edge and targeted technologies being developed to combat the novel coronavirus. New vaccines aim to teach the body’s immune system to recognize and destroy the coronavirus, but scientists are only now beginning to test them in people. Vaccines developed against TB and polio have already been used in millions of people and could offer a low-risk way to rev up the body’s first line of defense — the innate immune system — against a broad array of pathogens, including the coronavirus.

Chinese company, Contemporary Amperex Technology Co. Ltd. (CATL), this week announced a new battery technology that could revolutionise the electric vehicle market.

Established in 2011 and headquartered in Ningde, eastern China, CATL employs more than 24,000 people and has grown to become the world’s largest maker of lithium batteries. Amid surging demand for electric vehicles, its revenue soared by 54% last year. China, as a whole, installed 62.2 GWh of battery storage capacity last year, according to the China Automotive Battery Industry Innovation Alliance, of which CATL supplied 31.5 GWh for a market share of nearly 51%.

In addition to domestic sales, CATL supplies a wide range of carmakers internationally – including Tesla, BMW, Toyota, Honda, and Volkswagen. While sales have slumped more recently, due to the COVID-19 pandemic, CATL and its clients are expecting demand to return in 2021.

GlaxoSmithKline has penned deals offering its pandemic vaccine adjuvant to several developers of COVID-19 shots. And it needs to amp up supply for those companies to make enough doses of their final products.

Now, the British pharma said it will make 1 billion doses of the adjuvant, dubbed AS03, in 2021 for use in multiple COVID-19 vaccine candidates.

Theoretically, the adjuvant can increase the body’s immune response to the vaccine component it’s paired with, reducing the amount of vaccine needed for each shot and allowing manufacturers to make more doses.

“We have a researcher who was removed by the RCMP from the highest security laboratory that Canada has for reasons that government is unwilling to disclose. The intelligence remains secret. But what we know is that before she was removed, she sent one of the deadliest viruses on Earth, and multiple varieties of it to maximize the genetic diversity and maximize what experimenters in China could do with it, to a laboratory in China that does dangerous gain of function experiments. And that has links to the Chinese military.”

Gain of function experiments are when a natural pathogen is taken into the lab, made to mutate, and then assessed to see if it has become more deadly or infectious.

Most countries, including Canada, don’t do these kinds of experiments — because they’re considered too dangerous, Attaran said.


Newly-released access to information documents reveal details about a shipment of deadly pathogens last year from Canada’s National Microbiology Lab to China — confirming for the first time who sent them, what exactly was shipped, and where it went.

The virus shipments are not related to the outbreak of COVID-19 or research into the pandemic, Canadian officials said.

CBC News had already reported about the shipment of Ebola and Henipah viruses but there’s now confirmation one of the scientists escorted from the lab in Winnipeg amid an RCMP investigation last July was responsible for exporting the pathogens to the Wuhan Institute of Virology four months earlier.